FitLife Brands (FTLF) & CV Sciences (CVSI) Head to Head Review

FitLife Brands (OTCMKTS:FTLF) and CV Sciences (OTCMKTS:CVSI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Institutional & Insider Ownership

0.1% of CV Sciences shares are owned by institutional investors. 23.8% of FitLife Brands shares are owned by insiders. Comparatively, 10.1% of CV Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares FitLife Brands and CV Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FitLife Brands 2.36% 23.62% 6.37%
CV Sciences 20.73% 41.83% 33.90%

Earnings and Valuation

This table compares FitLife Brands and CV Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FitLife Brands $17.08 million 0.38 $510,000.00 N/A N/A
CV Sciences $48.24 million 11.02 $10.00 million $0.09 61.11

CV Sciences has higher revenue and earnings than FitLife Brands.

Volatility & Risk

FitLife Brands has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, CV Sciences has a beta of -0.72, suggesting that its share price is 172% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for FitLife Brands and CV Sciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FitLife Brands 0 0 0 0 N/A
CV Sciences 0 0 1 0 3.00

CV Sciences has a consensus target price of $8.00, suggesting a potential upside of 45.45%. Given CV Sciences’ higher possible upside, analysts clearly believe CV Sciences is more favorable than FitLife Brands.


CV Sciences beats FitLife Brands on 10 of the 12 factors compared between the two stocks.

About FitLife Brands

FitLife Brands, Inc. manufactures and markets nutritional supplements for health conscious consumers in the United States and internationally. The company offers weight loss, general health, and sports nutrition supplements, such as Censor, Cardio Cuts, and LipoRUSH DS; precision sports nutrition formulations for professional muscular development, including Amplify XL, Pump Fuel, and Flex Stack; weight loss and sports nutrition performance enhancing supplements for fitness enthusiasts comprising Isolate, Ultrakarbs, and NeuroLean; and men's health and weight loss formulations consisting of JXT5 and PyroStim. It also provides diet, health, and sports nutrition supplements and related products that support accelerated fitness and nutrition goals directly to athletic facilities, gyms, and independent retailers; and sports nutritionals, energy and sports drink products, and meal replacements. The company sells and markets its sports, weight loss, and general nutrition products under the NDS Nutrition Products, PMD, SirenLabs, and CoreActive brand names directly to franchise locations. It also markets its men's health and weight loss formulations under the Metis Nutrition brand through corporate and franchise stores; and sports nutritionals, energy and sports drink products, meal replacements, and weight loss products under the iSatori, BioGenetic Laboratories, and Energize brand names through approximately 25,000 retail locations, including specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

About CV Sciences

CV Sciences, Inc. operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape. CV Sciences, Inc. was founded in 2010 and is based in Las Vegas, Nevada.

Receive News & Ratings for FitLife Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FitLife Brands and related companies with's FREE daily email newsletter.